Myelodysplastic Syndromes | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2024
Myelodysplastic syndromes (MDS) are a heterogeneous collection of hematopoietic stem cell disorders that result in cytopenia and the risk of progression to acute myeloid leukemia (AML). Bristol Myers Squibb / Acceleron’s Reblozyl (luspatercept) for lower-risk adult MDS, Astex Pharmaceuticals’ Inqovi (decitabine and cedazuridine) for higher-risk adult MDS and refractory MDS, Geron Corporation’s Rytelo (imetelstat) for low- to intermediate-1-risk MDS with transfusion-dependent anemia, and Servier’s Tibsovo (ivosidenib) for relapsed or refractory MDS with an IDH1 mutation are effective treatments. Other pharmacological approaches to managing the disease (e.g., growth factor stimulants [e.g., erythropoietin-stimulating agents], lenalidomide [Revlimid, generics], hypomethylating agents [e.g., azacitidine]) are designed to ameliorate the symptoms and extend patients’ survival, although there is a significant gap in the treatment of refractory disease. The MDS pipeline is robust, and several projected market entrants are poised to penetrate both lower- and higher-risk subpopulations.
Questions answered
- How will the launches of Reblozyl (luspatercept), Inqovi (decitabine and cedazuridine), Rytelo (imetelstat), and Tibsovo (ivosidenib) change MDS treatment?
- What is the commercial outlook for current and emerging therapies for MDS?
- Which emerging therapies are most likely to have an impact on the MDS therapy market by 2033?
- How will the size of the MDS population change by 2033?
Geography: United States and EU5
Primary research: Six country-specific interviews with thought-leading hematologists supported by survey data collected for this study
Epidemiology: Diagnosed incident and diagnosed prevalent cases of MDS by country, drug-treated prevalent and incident cases of MDS, diagnosed incident and prevalent cases of MDS by morphology, and diagnosed prevalent cases by prognostic risk
Forecast: Drug-level sales and patient share of key MDS therapies through 2033
Drug treatments: Coverage of key current and emerging therapies
Product description
Niche & Rare Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.
Key feature
Niche & Rare Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
